Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna-Reference-Cited by-同舟云学术

Dalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna

Published:2018-04-05 Issue:5 Volume:67 Page:795-798
ISSN:1058-4838
Container-title:Clinical Infectious Diseases
language:en
Short-container-title:

Author:

Tobudic Selma¹,Forstner Christina¹²,Burgmann Heinz¹,Lagler Heimo¹,Ramharter Michael¹³,Steininger Christoph¹,Vossen Matthias (G)¹,Winkler Stefan¹,Thalhammer Florian¹

Affiliation:

1. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Austria

2. Institute for Infectious Diseases and Infection Control, Jena University Hospital

3. Bernhard Nocht Hospital for Tropical Diseases, Bernhard Nocht Institute for Tropical Medicine and University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Microbiology (medical)

Link

http://academic.oup.com/cid/article-pdf/67/5/795/25496796/ciy279.pdf

Reference15 articles.

1. The 2015 ESC guidelines for the management of infective endocarditis;Eur Heart J,2015

2. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection;Dunne;Clin Infect Dis,2016

3. Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011);Jones;Diagn Microbiol Infect Dis,2013

4. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers;Leighton;Antimicrob Agents Chemother,2004

5. Once-weekly dalbavancin versus daily conventional therapy for skin infection;Boucher;N Engl J Med,2014

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview;Global and Regional Health Technology Assessment;2024-07-29

2. Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network;Global and Regional Health Technology Assessment;2024-07-29

3. Enteroccocus and Endocarditis;Infectious Diseases;2024-06-11

4. Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review;Journal of Antimicrobial Chemotherapy;2024-06-06

5. Simulated Target Attainment of Multidose Regimens of Dalbavancin for Prolonged Durations of Therapy;Open Forum Infectious Diseases;2024-06